UroGen Pharma Ltd. (URGN) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Gross Margin ⢠Negative Equity ⢠Cash Burn URGN has strong gross margins and decent short-term liquidity, but persistent operating losses, negative equity, and heavy cash burn make the investment case high-risk and fundamentally weak.
Price Behavior
Key Price Behavior Insights: ⢠Breakout momentum ⢠Higher-low trend ⢠Stretched pullback Support Level: $24.00 to $24.30 Resistance Level: $26.06 URGN has trended sharply higher over the last month, breaking resistance and holding most gains, but the quick pullback from $26.06 to $24.11 signals stretched momentum and near-term volatility risk.
Sentiment & News
Key News Insights: ⢠Durable response ⢠Disease visibility ⢠Physician engagement UroGen is reinforcing ZUSDURI's clinical durability in LG-UTUC with strong ENVISION data while expanding disease-area visibility through a new physician recognition initiative.
AI Summary
URGN has shifted from a pure clinical bet to a commercialization test case: ENVISION durability and the permanent J-code materially improve the launch outlook, but the real investable question is whether ZUSDURI can convert reimbursement access into sustained revenue fast enough to offset heavy cash burn and fragile balance-sheet risk.
Description
UroGen Pharma Ltd. is a biotechnology company developing treatments for urothelial diseases and specialty cancers, using a biocompatible reverse thermal gel platform to modify drug delivery and exposure. Its pipeline includes UGN-102, currently in Phase III for several forms of non-muscle invasive urothelial cancer, and UGN-301 for high-grade disease, alongside a commercial offering based on its hydrogel technology. The company maintains licensing and development agreements with Allergan and Agenus and a research collaboration with MD Anderson, and is based in Princeton, New Jersey (incorporated 2004).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | URGN | UroGen Pharma Ltd. | UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points. | Closed | +22.3% |